Tufts Medical Center, Inc.

University of Kansas

New England Medical Center Hospitals. Inc.

Rq Bioscience, Inc.

Jiazhou Qiu

Andrew G Plaut

Todd Holyoak

Robert Sidong Qiu

Polypeptide agents useful in the treatment of IgA1 deposition diseases and methods of using such polypeptide agents. Methods of screening for inhibitors of IgA1 proteases and agents that inhibit IgA1 proteases are also disclosed.

IGA1 protease polypeptide agents and uses thereof

The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.

Clearance of abnormal IGA1 in IGA1 deposition diseases

The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed.

Combination therapy with IgA1 proteases

Treatment of IgA1 deposition diseases

Growing community of inventors

Westborough, MA, United States of America

Jiazhou Qiu